Advances in understanding and managing celiac disease: Pathophysiology and treatment strategies.

IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY World Journal of Gastroenterology Pub Date : 2024-09-21 DOI:10.3748/wjg.v30.i35.3932
Hao-Jie Ge, Xu-Lin Chen
{"title":"Advances in understanding and managing celiac disease: Pathophysiology and treatment strategies.","authors":"Hao-Jie Ge, Xu-Lin Chen","doi":"10.3748/wjg.v30.i35.3932","DOIUrl":null,"url":null,"abstract":"<p><p>In this editorial, we comment on an article published in the recent issue of the <i>World Journal of Gastroenterology</i>. Celiac disease (CeD) is a disease occurring in genetically susceptible individuals, which is mainly characterized by gluten intolerance in the small intestine and clinical symptoms such as abdominal pain, diarrhea, and malnutrition. Therefore, patients often need a lifelong gluten-free diet, which greatly affects the quality of life and expenses of patients. The gold standard for diagnosis is intestinal mucosal biopsy, combined with serological and genetic tests. At present, the lack of safe, effective, and satisfactory drugs for CeD is mainly due to the complexity of its pathogenesis, and it is difficult to find a perfect target to solve the multi-level needs of patients. In this editorial, we mainly review the pathological mechanism of CeD and describe the current experimental and improved drugs for various pathological aspects.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":"30 35","pages":"3932-3941"},"PeriodicalIF":4.3000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438662/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3748/wjg.v30.i35.3932","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In this editorial, we comment on an article published in the recent issue of the World Journal of Gastroenterology. Celiac disease (CeD) is a disease occurring in genetically susceptible individuals, which is mainly characterized by gluten intolerance in the small intestine and clinical symptoms such as abdominal pain, diarrhea, and malnutrition. Therefore, patients often need a lifelong gluten-free diet, which greatly affects the quality of life and expenses of patients. The gold standard for diagnosis is intestinal mucosal biopsy, combined with serological and genetic tests. At present, the lack of safe, effective, and satisfactory drugs for CeD is mainly due to the complexity of its pathogenesis, and it is difficult to find a perfect target to solve the multi-level needs of patients. In this editorial, we mainly review the pathological mechanism of CeD and describe the current experimental and improved drugs for various pathological aspects.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
了解和管理乳糜泻的进展:病理生理学和治疗策略。
在这篇社论中,我们对最近一期《世界胃肠病学杂志》上发表的一篇文章进行了评论。乳糜泻(Celiac disease,CeD)是一种发生在遗传易感人群中的疾病,主要特征是小肠麸质不耐受,临床症状包括腹痛、腹泻和营养不良。因此,患者往往需要终生无麸质饮食,这极大地影响了患者的生活质量和支出。诊断的金标准是肠粘膜活检,并结合血清学和基因检测。目前,CeD 缺乏安全、有效、满意的治疗药物,主要是由于其发病机制的复杂性,很难找到一个完美的靶点来解决患者的多层次需求。在这篇社论中,我们主要回顾了CeD的病理机制,并介绍了目前针对不同病理环节的实验药物和改良药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
World Journal of Gastroenterology
World Journal of Gastroenterology 医学-胃肠肝病学
CiteScore
7.80
自引率
4.70%
发文量
464
审稿时长
2.4 months
期刊介绍: The primary aims of the WJG are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in gastroenterology and hepatology.
期刊最新文献
Advances in artificial intelligence for predicting complication risks post-laparoscopic radical gastrectomy for gastric cancer: A significant leap forward. Comprehensive approach to esophageal variceal bleeding: From prevention to treatment. Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function. Improving early diagnosis of multiple endocrine neoplasia type 1 by assessing the gastrointestinal symptoms, hypercalcemia, and elevated serum gastrin. Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1